CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials

Overwhelming evidence shows the quality of reporting of randomised controlled trials (RCTs) is not optimal. Without transparent reporting, readers cannot judge the reliability and validity of trial findings nor extract information for systematic reviews. Recent methodological analyses indicate that inadequate reporting and design are associated with biased estimates of treatment effects. Such systematic error is seriously damaging to RCTs, which are considered the gold standard for evaluating interventions because of their ability to minimise or avoid bias. A group of scientists and editors developed the CONSORT (Consolidated Standards of Reporting Trials) statement to improve the quality of reporting of RCTs. It was first published in 1996 and updated in 2001. The statement consists of a checklist and flow diagram that authors can use for reporting an RCT. Many leading medical journals and major international editorial groups have endorsed the CONSORT statement. The statement facilitates critical appraisal and interpretation of RCTs. During the 2001 CONSORT revision, it became clear that explanation and elaboration of the principles underlying the CONSORT statement would help investigators and others to write or appraise trial reports. A CONSORT explanation and elaboration article was published in 2001 alongside the 2001 version of the CONSORT statement. After an expert meeting in January 2007, the CONSORT statement has been further revised and is published as the CONSORT 2010 Statement. This update improves the wording and clarity of the previous checklist and incorporates recommendations related to topics that have only recently received recognition, such as selective outcome reporting bias. This explanatory and elaboration document-intended to enhance the use, understanding, and dissemination of the CONSORT statement-has also been extensively revised. It presents the meaning and rationale for each new and updated checklist item providing examples of good reporting and, where possible, references to relevant empirical studies. Several examples of flow diagrams are included. The CONSORT 2010 Statement, this revised explanatory and elaboration document, and the associated website (www.consort-statement.org) should be helpful resources to improve reporting of randomised trials.

[1]  T. Lang Masking or blinding? An unscientific survey of mostly medical journal editors on the great debate. , 2000, MedGenMed : Medscape general medicine.

[2]  D. Moher,et al.  CONSORT for Reporting Randomized Controlled Trials in Journal and Conference Abstracts: Explanation and Elaboration , 2008, PLoS medicine.

[3]  T. Kaptchuk,et al.  Intentional Ignorance: A History of Blind Assessment and Placebo Controls in Medicine , 1998, Bulletin of the history of medicine.

[4]  A. Michalsen,et al.  Checklist for the qualitative evaluation of clinical studies with particular focus on external validity and model validity , 2006, BMC medical research methodology.

[5]  J. Noseworthy,et al.  The impact of blinding on the results of a randomized, placebo‐controlled multiple sclerosis clinical trial , 1994, Neurology.

[6]  S Greenland,et al.  Randomization, Statistics, and Causal Inference , 1990, Epidemiology.

[7]  P. Bath,et al.  Quality of full and final publications reporting acute stroke trials: a systematic review. , 1998, Stroke.

[8]  G H Guyatt,et al.  Effect of encouragement on walking test performance. , 1984, Thorax.

[9]  Nicholas C. Ide,et al.  Issues in the registration of clinical trials. , 2007, JAMA.

[10]  J. Stoner Cross-over Trials in Clinical Research , 2004 .

[11]  F. Davidoff,et al.  Changes to manuscripts during the editorial process: characterizing the evolution of a clinical paper. , 1998, JAMA.

[12]  A D Oxman,et al.  Randomisation to protect against selection bias in healthcare trials. , 2011, The Cochrane database of systematic reviews.

[13]  N L Geller,et al.  Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. , 1987, Biometrics.

[14]  R. Greenblatt,et al.  Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols , 2005, AIDS.

[15]  J. Hofland,et al.  Intravenous fluid restriction after major abdominal surgery: a randomized blinded clinical trial , 2009, Trials.

[16]  Douglas G. Altman,et al.  RANDOMISATION : ESSENTIAL FOR REDUCING BIAS , 1991 .

[17]  D. Rennie Reporting randomized controlled trials. An experiment and a call for responses from readers. , 1995, JAMA.

[18]  S. Goodman Toward Evidence-Based Medical Statistics. 1: The P Value Fallacy , 1999, Annals of Internal Medicine.

[19]  K. Schulz,et al.  Sample size calculations in randomised trials: mandatory and mystical , 2005, The Lancet.

[20]  D. DeMets,et al.  The randomized clinical trial: bias in analysis. , 1981, Circulation.

[21]  M. Tramèr,et al.  Impact of covert duplicate publication on meta-analysis: a case study , 1997, BMJ.

[22]  J M Lachin,et al.  Statistical considerations in the intent-to-treat principle. , 2000, Controlled clinical trials.

[23]  K. Ah-See,et al.  A qualitative assessment of randomized controlled trials in otolaryngology , 1998, The Journal of Laryngology & Otology.

[24]  B. Demichelis,et al.  Completeness of reporting trial results: effect on physicians' willingness to prescribe , 1994, The Lancet.

[25]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. , 2001, Journal of the American Podiatric Medical Association.

[26]  J. Wittes,et al.  Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. , 1991, JAMA.

[27]  M. Martínez-González,et al.  Intention to treat analysis is related to methodological quality , 2000, BMJ : British Medical Journal.

[28]  L. Kjaergard,et al.  Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ , 2002, BMJ : British Medical Journal.

[29]  J. Concato,et al.  The Risk of Determining Risk with Multivariable Models , 1993, Annals of Internal Medicine.

[30]  D. Altman,et al.  Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research , 2004, Canadian Medical Association Journal.

[31]  D. Streiner Missing data and the trouble with LOCF , 2008, Evidence-based mental health.

[32]  Quoting intermediate analyses can only mislead , 1997, BMJ.

[33]  D. Rennie,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative , 2003, BMJ : British Medical Journal.

[34]  S. Evans,et al.  Selective reporting in clinical trials: analysis of trial protocols accepted by The Lancet , 2008, The Lancet.

[35]  D. Sackett,et al.  Controversy in counting and attributing events in clinical trials. , 1979, The New England journal of medicine.

[36]  K. Schulz,et al.  Subverting randomization in controlled trials. , 1995, JAMA.

[37]  D. Moher,et al.  Statistical power, sample size, and their reporting in randomized controlled trials. , 1994, JAMA.

[38]  Steven Reid A different look , 2008 .

[39]  D. Machin,et al.  Intention to treat--who should use ITT? , 1993, British Journal of Cancer.

[40]  Alex H S Harris,et al.  The Accuracy of Abstracts in Psychology Journals , 2002, The Journal of psychology.

[41]  D. Berry,et al.  Interim analyses in clinical trials: classical vs. Bayesian approaches. , 1985, Statistics in medicine.

[42]  D G Altman,et al.  Statistics in medical journals. , 1982, Statistics in medicine.

[43]  D. Moher,et al.  Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. , 2008, Annals of internal medicine.

[44]  R. Horton,et al.  Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. , 2005, The Medical journal of Australia.

[45]  R Peto,et al.  Why do we need some large, simple randomized trials? , 1984, Statistics in medicine.

[46]  S. Assmann,et al.  Subgroup analysis and other (mis)uses of baseline data in clinical trials , 2000, The Lancet.

[47]  S M Gore,et al.  Misuse of statistical methods: critical assessment of articles in BMJ from January to March 1976. , 1977, British medical journal.

[48]  P. Lane Handling drop‐out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches , 2008, Pharmaceutical statistics.

[49]  O. Hjalmarson,et al.  Early versus delayed neonatal administration of a synthetic surfactant: the judgment of Osiris , 1992 .

[50]  Amir Herman,et al.  Intention-to-treat analysis and accounting for missing data in orthopaedic randomized clinical trials. , 2009, Journal of Bone and Joint Surgery. American volume.

[51]  Harlan M Krumholz,et al.  Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. , 2008, JAMA.

[52]  Douglas G Altman,et al.  Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols , 2008, BMJ : British Medical Journal.

[53]  B. Beermann,et al.  Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications , 2003, BMJ : British Medical Journal.

[54]  J. Ware,et al.  Interpreting incomplete data in studies of diet and weight loss. , 2003, The New England journal of medicine.

[55]  Satish Iyengar,et al.  Prevention of depression in at-risk adolescents: a randomized controlled trial. , 2009, JAMA.

[56]  I. Chalmers,et al.  The Landscape and Lexicon of Blinding in Randomized Trials , 2002, Annals of Internal Medicine.

[57]  D. Spiegelhalter,et al.  Issues in data monitoring and interim analysis of trials. , 2005, Health technology assessment.

[58]  I. Chalmers From optimism to disillusion about commitment to transparency in the medico-industrial complex. , 2006, Journal of the Royal Society of Medicine.

[59]  M. Smithson Statistics with confidence , 2000 .

[60]  R. J. Hayes,et al.  Blinding and exclusions after allocation in randomised controlled trials: survey of published parallel group trials in obstetrics and gynaecology , 1996, BMJ.

[61]  G. Yamey,et al.  The Impact of Open Access upon Public Health , 2006, PLoS Medicine.

[62]  David L Streiner,et al.  The Case of the Missing Data: Methods of Dealing with Dropouts and other Research Vagaries , 2002, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[63]  J Savulescu,et al.  Are research ethics committees behaving unethically? Some suggestions for improving performance and accountability , 1996, BMJ.

[64]  Donald A Williamson,et al.  Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. , 2009, The New England journal of medicine.

[65]  D G Altman,et al.  Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons , 1995, BMJ.

[66]  R. Holubkov,et al.  Carvedilol for children and adolescents with heart failure: a randomized controlled trial. , 2007, JAMA.

[67]  Douglas G Altman,et al.  How to randomise , 1999, BMJ.

[68]  Nilay D Shah,et al.  Chronic care model and shared care in diabetes: randomized trial of an electronic decision support system. , 2008, Mayo Clinic proceedings.

[69]  E. Antman,et al.  Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial , 2009, The Lancet.

[70]  W. S. Fields,et al.  Joint study of extracranial arterial occlusion. V. Progress report of prognosis following surgery or nonsurgical treatment for transient cerebral ischemic attacks and cervical carotid artery lesions. , 1970 .

[71]  Douglas G Altman,et al.  Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.

[72]  P Middleton,et al.  Technical editing of research reports in biomedical journals. , 2007, The Cochrane database of systematic reviews.

[73]  Salim Yusuf,et al.  Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[74]  T R Einarson,et al.  Quality of nonstructured and structured abstracts of original research articles in the British Medical Journal, the Canadian Medical Association Journal and the Journal of the American Medical Association. , 1994, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[75]  I. Olkin,et al.  Improving the quality of reporting of randomized controlled trials. The CONSORT statement. , 1996, JAMA.

[76]  S Greenland,et al.  Principles of multilevel modelling. , 2000, International journal of epidemiology.

[77]  Denis Xavier,et al.  Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial , 2008, The Lancet.

[78]  Carl Heneghan,et al.  What is missing from descriptions of treatment in trials and reviews? , 2008, BMJ : British Medical Journal.

[79]  C. Ko,et al.  Reporting Randomized, Controlled Trials , 2002, Diseases of the colon and rectum.

[80]  G H Guyatt,et al.  A Consumer's Guide to Subgroup Analyses , 1992, Annals of Internal Medicine.

[81]  Douglas G Altman,et al.  Statistics Notes: Units of analysis , 1997, BMJ.

[82]  Curtis L. Meinert,et al.  A proposal for structured reporting of randomized controlled trials. The Standards of Reporting Trials Group. , 1994, JAMA.

[83]  D. Moher,et al.  Endorsement of the CONSORT Statement by high impact factor medical journals: a survey of journal editors and journal 'Instructions to Authors' , 2008, Trials.

[84]  S. Schor,et al.  Statistical evaluation of medical journal manuscripts. , 1966, JAMA.

[85]  E. Franssen How to Report Statistics in Medicine , 2008, Nature Medicine.

[86]  F. Song,et al.  Evaluating non-randomised intervention studies. , 2003, Health technology assessment.

[87]  Douglas G. Altman,et al.  Explanation and Elaboration , 2022 .

[88]  R. Temple,et al.  FDA perspective on trials with interim efficacy evaluations , 2006, Statistics in medicine.

[89]  Joan Webster,et al.  Routine care of peripheral intravenous catheters versus clinically indicated replacement: randomised controlled trial , 2008, BMJ : British Medical Journal.

[90]  S. Goodman,et al.  The Use of Predicted Confidence Intervals When Planning Experiments and the Misuse of Power When Interpreting Results , 1994, Annals of Internal Medicine.

[91]  D. Juurlink,et al.  The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903] , 2003, BMC clinical pharmacology.

[92]  C. Ramsay,et al.  Minimal access surgery compared with medical management for chronic gastro-oesophageal reflux disease: UK collaborative randomised trial , 2008, BMJ : British Medical Journal.

[93]  B. Muthén,et al.  Adaptive designs for randomized trials in public health. , 2009, Annual review of public health.

[94]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[95]  D. Berman,et al.  Optimal medical therapy with or without PCI for stable coronary disease. , 2007, The New England journal of medicine.

[96]  S. Pocock,et al.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration , 2007, Annals of Internal Medicine [serial online].

[97]  M. Palmer Clinical Trials: A Practical Approach , 1985 .

[98]  R. Horton,et al.  [Uniform requirements for manuscripts submitted to biomedical journals. The International Committee of Medical Journal Editors]. , 1997, Revista de sanidad e higiene publica.

[99]  C. Fowler,et al.  Randomised evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia. , 2005, Health technology assessment.

[100]  D. Moher,et al.  Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review , 2006, The Medical journal of Australia.

[101]  J. Tukey Some thoughts on clinical trials, especially problems of multiplicity. , 1977, Science.

[102]  T C Chalmers,et al.  Meta-analysis of clinical trials as a scientific discipline. I: Control of bias and comparison with large co-operative trials. , 1987, Statistics in medicine.

[103]  K. Khan,et al.  Logistic regression models in obstetrics and gynecology literature. , 1999, Obstetrics and gynecology.

[104]  Isabelle Boutron,et al.  Reporting of safety results in published reports of randomized controlled trials. , 2009, Archives of internal medicine.

[105]  S. Pocock,et al.  When to stop a clinical trial. , 1992, BMJ.

[106]  C Cates,et al.  Confidence intervals for the number needed to treat , 1999 .

[107]  G H Guyatt,et al.  Users' guides to the medical literature: XIV. How to decide on the applicability of clinical trial results to your patient. Evidence-Based Medicine Working Group. , 1998, JAMA.

[108]  Lisa Bero,et al.  Factors Associated with Findings of Published Trials of Drug–Drug Comparisons: Why Some Statins Appear More Efficacious than Others , 2007, PLoS medicine.

[109]  Paul Gallo,et al.  PhRMA Working Group on Adaptive Designs: Introduction to the Full White Paper , 2006 .

[110]  S. Hollis,et al.  What is meant by intention to treat analysis? Survey of published randomised controlled trials , 1999, BMJ.

[111]  Douglas G. Altman,et al.  Statistics with confidence: Confidence intervals and statistical guidelines . , 1990 .

[112]  K. Lee,et al.  Clinical trials in acute myocardial infarction: should we adjust for baseline characteristics? , 2000, American heart journal.

[113]  G. Enas,et al.  Baseline Comparability in Clinical Trials: Prevention of “Poststudy Anxiety” , 1990 .

[114]  Stephen Senn,et al.  Cross-over trials in clinical research , 1993 .

[115]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[116]  R. Kruse,et al.  Intention-to-treat analysis: who is in? Who is out? , 2002, The Journal of family practice.

[117]  J. Lachin Properties of simple randomization in clinical trials. , 1988, Controlled clinical trials.

[118]  D. Spiegelhalter,et al.  Reported use of data monitoring committees in the main published reports of randomized controlled trials: a cross-sectional study , 2004, Clinical trials.

[119]  Alan Cantor,et al.  The uncertainty principle and industry-sponsored research , 2000, The Lancet.

[120]  K. Dickersin How important is publication bias? A synthesis of available data. , 1997, AIDS education and prevention : official publication of the International Society for AIDS Education.

[121]  R. Horton,et al.  Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. , 2005, Saudi medical journal.

[122]  J. Hall,et al.  Misuse of statistical methods in the Australasian surgical literature. , 1982, The Australian and New Zealand journal of surgery.

[123]  Douglas G Altman,et al.  Missing outcomes in randomized trials: addressing the dilemma , 2009, Open medicine : a peer-reviewed, independent, open-access journal.

[124]  D Moher,et al.  CONSORT: an evolving tool to help improve the quality of reports of randomized controlled trials. Consolidated Standards of Reporting Trials. , 1998, JAMA.

[125]  A. Culyer,et al.  Community provision of hearing aids and related audiology services. , 2000, Health technology assessment.

[126]  C. Junker Adherence to published standards of reporting: a comparison of placebo-controlled trials published in English or German. , 1998, JAMA.

[127]  S. Pocock,et al.  Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. , 2006, JAMA.

[128]  D. DeMets,et al.  The agonising negative trend in monitoring of clinical trials , 1999, The Lancet.

[129]  John P A Ioannidis,et al.  Limitations are not properly acknowledged in the scientific literature. , 2007, Journal of clinical epidemiology.

[130]  Frederick Mosteller,et al.  Reporting on methods in clinical trials. , 1982, The New England journal of medicine.

[131]  A. Astrup,et al.  Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study , 2009, The Lancet.

[132]  B. Koes,et al.  Supervised exercise therapy versus usual care for patellofemoral pain syndrome: an open label randomised controlled trial , 2009, BMJ : British Medical Journal.

[133]  Duff Waring,et al.  Turning a blind eye: the success of blinding reported in a random sample of randomised, placebo controlled trials , 2004, BMJ : British Medical Journal.

[134]  J. Cuzick,et al.  More on zidovudine in asymptomatic HIV infection. , 1994, The New England journal of medicine.

[135]  A. Hrõbjartsson,et al.  Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study , 2005, BMJ : British Medical Journal.

[136]  G. Guyatt,et al.  Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. , 2001, JAMA.

[137]  B. Psaty,et al.  Generalizability of the results of randomized trials. , 2008, Archives of internal medicine.

[138]  U. Siebert,et al.  Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. , 2009, The New England journal of medicine.

[139]  D L Sackett,et al.  An assessment of clinically useful measures of the consequences of treatment. , 1988, The New England journal of medicine.

[140]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[141]  Sally Hopewell,et al.  Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant evidence: a status report. , 2007, Journal of the Royal Society of Medicine.

[142]  M C Weinstein,et al.  Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.

[143]  L. Wright,et al.  A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infant , 1994 .

[144]  G. Guyatt,et al.  Users' guides to the medical literature. , 1993, JAMA.

[145]  P. Gøtzsche Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. , 1989, Controlled clinical trials.

[146]  Michael Clarke,et al.  Non-random Reflections on Health Services Research , 1998, BMJ.

[147]  T C Chalmers,et al.  The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. , 1978, The New England journal of medicine.

[148]  P. Korenblat,et al.  A randomized double-blind trial , 2003 .

[149]  G. Piaggio,et al.  The reporting of methods for reducing and detecting bias: an example from the WHO Misoprostol Third Stage of Labour equivalence randomised controlled trial , 2003, BMC medical research methodology.

[150]  R. Findling,et al.  Controlled Clinical Trial of Zolpidem for the Treatment of Insomnia Associated With Attention-Deficit/ Hyperactivity Disorder in Children 6 to 17 Years of Age , 2009, Pediatrics.

[151]  J. Hilden,et al.  Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. , 2007, International journal of epidemiology.

[152]  A. Tonks,et al.  A clinical trials register for Europe , 2002, BMJ : British Medical Journal.

[153]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[154]  S. Senn,et al.  Base Logic: Tests of Baseline Balance in Randomized Clinical Trials , 1995 .

[155]  Douglas G. Altman,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[156]  D G Altman,et al.  Calculating the number needed to treat for trials where the outcome is time to an event , 1999, BMJ.

[157]  D G Altman,et al.  Statistics Notes: Interaction 2: compare effect sizes not P values , 1996, BMJ.

[158]  T C Chalmers,et al.  Ascorbic acid for the common cold. A prophylactic and therapeutic trial. , 1975, JAMA.

[159]  Patrick J. Kelly,et al.  A Practical Comparison of Group-Sequential and Adaptive Designs , 2005, Journal of biopharmaceutical statistics.

[160]  P. Holland Statistics and Causal Inference , 1985 .

[161]  M. Outzen Splint for Base-of-Thumb Osteoarthritis: A Randomized Trial , 2010 .

[162]  T. Wachs,et al.  CONSORT for reporting randomised trials in journal and conference abstracts , 2008 .

[163]  B. Morrey,et al.  Ardeparin Sodium for Extended Out-of-Hospital Prophylaxis against Venous Thromboembolism after Total Hip or Knee Replacement , 2000, Annals of Internal Medicine.

[164]  P. Gøtzsche,et al.  Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis , 1995, BMJ.

[165]  J. Bodfish,et al.  Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. , 1999, The New England journal of medicine.

[166]  Douglas G Altman,et al.  Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. , 2006, JAMA.

[167]  T O Jefferson,et al.  Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.

[168]  A. Catanzaro,et al.  Comparison of Oral Fluconazole and Itraconazole for Progressive, Nonmeningeal Coccidioidomycosis , 2000, Annals of Internal Medicine.

[169]  Isabelle Boutron,et al.  Splint for Base-of-Thumb Osteoarthritis , 2009, Annals of Internal Medicine.

[170]  J. Donovan,et al.  Reporting on quality of life in randomised controlled trials: bibliographic study , 1998, BMJ.

[171]  C D Naylor,et al.  Measured Enthusiasm: Does the Method of Reporting Trial Results Alter Perceptions of Therapeutic Effectiveness? , 1992, Annals of Internal Medicine.

[172]  Saravu R Narahari,et al.  Evidence-based approaches for the Ayurvedic traditional herbal formulations: toward an Ayurvedic CONSORT model. , 2008, Journal of alternative and complementary medicine.

[173]  Jesper Nielsen,et al.  Laypersons' understanding of relative risk reductions: Randomised cross-sectional study , 2008, BMC Medical Informatics Decis. Mak..

[174]  D. Altman Comparability of Randomised Groups , 1985 .

[175]  Douglas G. Altman,et al.  Systematic reviews in health care : meta-analysis in context , 2008 .

[176]  S. Pocock,et al.  Stopping rules and estimation problems in clinical trials. , 1988, Statistics in medicine.

[177]  N. Black CONSORT , 1996, The Lancet.

[178]  C. Meinert Beyond CONSORT: need for improved reporting standards for clinical trials. Consolidated Standards of Reporting Trials. , 1998, JAMA.

[179]  The-Open-Study-Infants-Respiratory-Insufficiency-S Early versus delayed neonatal administration of a synthetic surfactant — The judgment of OSIRIS , 1992 .

[180]  L. Katz,et al.  Uterine Exteriorization Compared With In Situ Repair at Cesarean Delivery: A Randomized Controlled Trial , 2008, Obstetrics and gynecology.

[181]  J. Manson,et al.  Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. , 2008, JAMA.

[182]  C. Gluud,et al.  Randomized clinical trials in Hepatology: Predictors of quality , 1999, Hepatology.

[183]  C. Meinert Masked monitoring in clinical trials--blind stupidity? , 1998, New England Journal of Medicine.

[184]  M. Pittler Systematic Reviews in Health Care: Meta‐analysis in Context , 2010 .

[185]  D G Altman,et al.  The scandal of poor medical research , 1994, BMJ.

[186]  D. Rubin,et al.  Intention‐to‐treat analysis and the goals of clinical trials , 1995, Clinical pharmacology and therapeutics.

[187]  J. Tyson,et al.  A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. , 1994, The New England journal of medicine.

[188]  Ian R White,et al.  Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals , 2004, Clinical trials.

[189]  G. Norman,et al.  Randomized controlled trials. , 2004, AJR. American journal of roentgenology.

[190]  Gordon H Guyatt,et al.  Randomized trials stopped early for benefit: a systematic review. , 2005, JAMA.

[191]  A Oakley,et al.  Assessment of generalisability in trials of health interventions: suggested framework and systematic review , 2006, BMJ : British Medical Journal.

[192]  Christian Gluud,et al.  Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? , 2003, JAMA.

[193]  J P Kassirer,et al.  Clinical trials and meta-analysis. What do they do for us? , 1992, The New England journal of medicine.

[194]  D. Rennie,et al.  Stopping medical research to save money: a broken pact with researchers and patients. , 2003, JAMA.

[195]  D. Rennie CONSORT revised--improving the reporting of randomized trials. , 2001, JAMA.

[196]  Holger J Schünemann,et al.  Misuse of Baseline Comparison Tests and Subgroup Analyses in Surgical Trials , 2006, Clinical orthopaedics and related research.

[197]  Ezekiel Uba Nwose,et al.  The Lancet Handbook of Essential Concepts in Clinical Research , 2007 .

[198]  D. Moher,et al.  The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration , 2001, Annals of Internal Medicine.

[199]  C. Adams,et al.  Content and quality of 2000 controlled trials in schizophrenia over 50 years , 1998, BMJ.

[200]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.

[201]  A. Hrõbjartsson,et al.  Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. , 2004, JAMA.

[202]  D. Grimes,et al.  Preventing IUCD‐related pelvic infection: The efficacy of prophylactic doxycycline at insertion , 1991, British journal of obstetrics and gynaecology.

[203]  A. LaCroix,et al.  Low-Dose Hydrochlorothiazide and Preservation of Bone Mineral Density in Older Adults , 2000, Annals of Internal Medicine.

[204]  Tom Lang,et al.  How to Report Statistics in Medicine: Annotated Guidelines for Authors, Editors, and Reviewers , 1997 .

[205]  U. Haag Technologies for Automating Randomized Treatment Assignment in Clinical Trials , 1998 .

[206]  Call for Comments on a Proposal To Improve Reporting of Clinical Trials in the Biomedical Literature , 1994, Annals of Internal Medicine.

[207]  N. Talley,et al.  Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. , 1996, The American journal of gastroenterology.

[208]  J J Shuster,et al.  Median follow-up in clinical trials. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[209]  J. H. Mitchell Medical aid to vietnam. , 1969, The Medical journal of Australia.

[210]  C Weijer,et al.  A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group. , 1998, Journal of clinical epidemiology.

[211]  M Docherty,et al.  The case for structuring the discussion of scientific papers , 1999, BMJ.

[212]  S. Shapiro,et al.  The intention-to-treat approach in randomized controlled trials: Are authors saying what they do and doing what they say? , 2007, Clinical trials.

[213]  M. Boyle,et al.  Treatment of attention-deficit/hyperactivity disorder. , 1999, Evidence report/technology assessment.

[214]  J. Deeks,et al.  Effect of needle length on incidence of local reactions to routine immunisation in infants aged 4 months: randomised controlled trial , 2000, BMJ : British Medical Journal.

[215]  D. G. Altman,et al.  Review of survival analyses published in cancer journals. , 1995, British Journal of Cancer.

[216]  P. Gøtzsche,et al.  Blinding during data analysis and writing of manuscripts. , 1996, Controlled clinical trials.

[217]  D. Altman,et al.  Reporting on Statistical Methods To Adjust for Confounding: A Cross-Sectional Survey , 2002, Annals of Internal Medicine.

[218]  P. Rothwell,et al.  External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.

[219]  I. Leviton,et al.  Registering clinical trials. , 2003, Journal of the American Medical Association (JAMA).

[220]  Giuseppe Mancia,et al.  Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) , 2000, The Lancet.

[221]  J. Ioannidis,et al.  Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement , 2004, Annals of Internal Medicine.

[222]  Guosheng Yin,et al.  Fundamentals of Clinical Trials , 2012 .

[223]  D. Elbourne,et al.  A randomised controlled trial of care of the perineum during second stage of normal labour , 1998, British journal of obstetrics and gynaecology.

[224]  Mike Clarke,et al.  Standardising outcomes for clinical trials and systematic reviews , 2007, Trials.

[225]  P. Rothwell,et al.  Factors That Can Affect the External Validity of Randomised Controlled Trials , 2006, PLoS clinical trials.

[226]  R. Horton The rhetoric of research , 1995, BMJ.

[227]  Lois Ann Colaianni,et al.  Uniform Requirements for Manuscripts Submitted to Biomedical Journals , 1991, The Medical journal of Australia.

[228]  D. Campbell Factors relevant to the validity of experiments in social settings. , 1957, Psychological bulletin.

[229]  S. Golder,et al.  The effectiveness and cost-effectiveness of prophylactic removal of wisdom teeth. , 2000, Health technology assessment.

[230]  Douglas G Altman,et al.  Epidemiology and reporting of randomised trials published in PubMed journals , 2005, The Lancet.

[231]  T. Mills,et al.  Measuring Health: A Guide to Rating Scales and Questionnaires , 2006 .

[232]  S. Pocock,et al.  Statistical problems in the reporting of clinical trials. A survey of three medical journals. , 1987, The New England journal of medicine.

[233]  P Armitage,et al.  The role of randomization in clinical trials. , 1982, Statistics in medicine.

[234]  L. Sadler,et al.  A randomised controlled trial and meta‐analysis of active management of labour , 2000, BJOG : an international journal of obstetrics and gynaecology.

[235]  James Hartley,et al.  Obtaining information accurately and quickly: are structured abstracts more efficient? , 1996, J. Inf. Sci..

[236]  S. Yusuf,et al.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial , 2008, The Lancet.

[237]  Emmanuel Lagarde,et al.  Randomized, Controlled Intervention Trial of Male Circumcision for Reduction of HIV Infection Risk: The ANRS 1265 Trial , 2005, PLoS medicine.

[238]  D. Moher,et al.  CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials , 2010, Journal of pharmacology & pharmacotherapeutics.

[239]  L. Rajmil Health measurement scales. A practical guide to their development and use, 3rd ed , 2005 .

[240]  K. Barnhart,et al.  Multicenter Comparison of the Contraceptive Ring and Patch: A Randomized Controlled Trial , 2008, Obstetrics and gynecology.

[241]  Philippe Ravaud,et al.  Reporting of sample size calculation in randomised controlled trials: review , 2009, BMJ : British Medical Journal.

[242]  Asbjørn Hróbjartsson,et al.  Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors , 2006, Clinical trials.

[243]  S. Pocock Statistical Aspects of Clinical Trial Design , 1982 .

[244]  D. Tate,et al.  Effects of Internet behavioral counseling on weight loss in adults at risk for type 2 diabetes: a randomized trial. , 2003, JAMA.

[245]  C. Adams,et al.  Unpublished rating scales: A major source of bias in randomised controlled trials of treatments for schizophrenia , 2000, British Journal of Psychiatry.

[246]  D G Altman,et al.  Statistics notes: Interaction 3: How to examine heterogeneity , 1996 .

[247]  R. Anderson,et al.  Impact and Process Evaluation of Integrated Community and Clinic-Based HIV-1 Control: A Cluster-Randomised Trial in Eastern Zimbabwe , 2007, PLoS medicine.

[248]  G D Murray,et al.  Promoting good research practice , 2000, Statistical methods in medical research.

[249]  J. Ioannidis,et al.  Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. , 2001, JAMA.

[250]  V. Barbour,et al.  The impact of open access upon public health. , 2006, Bulletin of the World Health Organization.

[251]  F. McAlister Applying the Results of Systematic Reviews at the Bedside , 2008 .

[252]  B. Djulbegovic,et al.  Pharmaceutical industry sponsorship and research outcome and quality: systematic review , 2003, BMJ : British Medical Journal.

[253]  I. McDowell,et al.  Measuring health: A guide to rating scales and questionnaires, 3rd ed. , 2006 .

[254]  S. Bolton Independence and Statistical Inference in Clinical Trial Designs: A Tutorial Review , 1998, Journal of clinical pharmacology.

[255]  J H Ellenberg,et al.  Analysis of clinical trials by treatment actually received: is it really an option? , 1991, Statistics in medicine.

[256]  J. Ioannidis,et al.  Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias , 2008, PloS one.

[257]  ISIS-1 Collaborative Group RANDOMISED TRIAL OF INTRAVENOUS ATENOLOL AMONG 16 027 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-1 , 1986, The Lancet.

[258]  C. Meinert,et al.  Treatment effects monitoring committees and early stopping in large clinical trials , 2004, Clinical trials.

[259]  Peter C Gøtzsche,et al.  Believability of relative risks and odds ratios in abstracts: cross sectional study , 2006, BMJ : British Medical Journal.

[260]  Gordon H Guyatt,et al.  In the Era of Systematic Reviews, Does the Size of an Individual Trial Still Matter? , 2008, PLoS medicine.

[261]  R. Ness-Abramof Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study , 2010 .

[262]  P. Bower,et al.  Conceptual framework and systematic review of the effects of participants' and professionals' preferences in randomised controlled trials. , 2005, Health technology assessment.

[263]  H. Williams,et al.  How well are randomized controlled trials reported in the dermatology literature? , 2000, Archives of dermatology.

[264]  T. Lang,et al.  How to Report Statistics in Medicine: Annotated Guidelines for Authors , 1997 .

[265]  J. PérezMartín,et al.  [International Committee of Medical Journal Editors]. , 2008, Revista alergia Mexico.

[266]  T C Chalmers,et al.  Cumulative meta-analysis of therapeutic trials for myocardial infarction. , 1992, The New England journal of medicine.

[267]  D. Henson,et al.  The effectiveness of the Heidelberg Retina Tomograph and laser diagnostic glaucoma scanning system (GDx) in detecting and monitoring glaucoma. , 2005, Health technology assessment.

[268]  U Grouven,et al.  Logistic regression models used in medical research are poorly presented , 1996, BMJ.

[269]  N. Nagelkerke,et al.  Estimating treatment effects in randomized clinical trials in the presence of non-compliance. , 2000, Statistics in medicine.

[270]  M. Staun,et al.  Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. , 2000, Gastroenterology.

[271]  E. Verhagen,et al.  Effect of unsupervised home based proprioceptive training on recurrences of ankle sprain: randomised controlled trial , 2009, BMJ : British Medical Journal.

[272]  M. Manary,et al.  Supplementary feeding with either ready-to-use fortified spread or corn-soy blend in wasted adults starting antiretroviral therapy in Malawi: randomised, investigator blinded, controlled trial , 2009, BMJ : British Medical Journal.

[273]  Sangeeta Mehta,et al.  Vasopressin versus norepinephrine infusion in patients with septic shock. , 2008, The New England journal of medicine.

[274]  D. Sackett,et al.  The number needed to treat: a clinically useful measure of treatment effect , 1995, BMJ.

[275]  C. R.J.,et al.  Statistics with Confidence (2nd ed.) , 2003 .

[276]  W. Elliott Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial , 2009 .

[277]  V. Torri,et al.  Quality, evolution, and clinical implications of randomized, controlled trials on the treatment of lung cancer. A lost opportunity for meta-analysis. , 1989, JAMA.

[278]  G. Guyatt,et al.  In the dark: the reporting of blinding status in randomized controlled trials. , 2002, Journal of clinical epidemiology.

[279]  Kenneth F Schulz,et al.  Randomised trials, human nature, and reporting guidelines , 1996, The Lancet.

[280]  F. Davidoff News from the International Committee of Medical Journal Editors , 2000, Annals of Internal Medicine.

[281]  David Moher,et al.  Reporting Randomized, Controlled Trials of Herbal Interventions: An Elaborated CONSORT Statement , 2006, Annals of Internal Medicine.

[282]  D. Moher,et al.  Improving the reporting of pragmatic trials: an extension of the CONSORT statement , 2008, BMJ : British Medical Journal.

[283]  R. Collins,et al.  Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials , 2001, The Lancet.

[284]  Å. Westin,et al.  Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety , 2000, BMJ : British Medical Journal.

[285]  J. Hall,et al.  Methodologic standards in surgical trials. , 1996, Surgery.

[286]  D. Sackett Turning a blind eye:Why we don't test for blindness at the end of our trials , 2004, BMJ : British Medical Journal.

[287]  S. Pocock,et al.  Trials stopped early: too good to be true? , 1999, The Lancet.

[288]  A J Sutton,et al.  Publication and related biases. , 2000, Health technology assessment.

[289]  Peter Fonagy,et al.  Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data , 2004, The Lancet.

[290]  A. Colevas,et al.  Adverse event reporting in publications compared with sponsor database for cancer clinical trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[291]  R. Simes Publication bias: the case for an international registry of clinical trials. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[292]  J L Hutton,et al.  Assessing the potential for bias in meta-analysis due to selective reporting of subgroup analyses within studies. , 2000, Statistics in medicine.

[293]  B L Humphreys,et al.  Structured abstracts in MEDLINE, 1989-1991. , 1995, Bulletin of the Medical Library Association.

[294]  M Egger,et al.  The causes and effects of socio-demographic exclusions from clinical trials. , 2005, Health technology assessment.

[295]  Leah G Ward,et al.  Accuracy of Abstracts for Original Research Articles in Pharmacy Journals , 2004, The Annals of pharmacotherapy.

[296]  N. Talley,et al.  Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. , 1996, The American journal of gastroenterology.

[297]  M. Gardner,et al.  More informative abstracts revisited. , 1990, The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association.

[298]  J. Karlawish,et al.  The continuing unethical conduct of underpowered clinical trials. , 2002, JAMA.

[299]  Douglas G Altman,et al.  Analysis and reporting of factorial trials: a systematic review. , 2003, JAMA.

[300]  C. Weijer,et al.  Reporting the study populations of clinical trials. Clear transmission or static on the line? , 2000, Journal of clinical epidemiology.

[301]  P. Gøtzsche Reference bias in reports of drug trials. , 1987, British medical journal.

[302]  T. Treasure,et al.  Minimisation: the platinum standard for trials? , 1998, BMJ.

[303]  M Egger,et al.  Value of flow diagrams in reports of randomized controlled trials. , 2001, JAMA.

[304]  John Hoey,et al.  Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors , 2005, The Lancet.

[305]  Brian Hutton,et al.  Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? , 2005, Clinical trials.

[306]  K. Papp,et al.  Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study , 2008, The Lancet.

[307]  Sally Hopewell,et al.  The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed , 2010, BMJ : British Medical Journal.

[308]  P. Mease,et al.  Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial , 2000, The Lancet.

[309]  D. Altman,et al.  CONSORT statement: extension to cluster randomised trials , 2004, BMJ : British Medical Journal.

[310]  Sergio Sismondo,et al.  Pharmaceutical company funding and its consequences: a qualitative systematic review. , 2008, Contemporary clinical trials.

[311]  J C Bailar,et al.  Guidelines for statistical reporting in articles for medical journals. Amplifications and explanations. , 1988, Annals of internal medicine.

[312]  D. Ashby,et al.  Randomized controlled trials in cystic fibrosis (1966–1997) categorized by time, design, and intervention , 2000, Pediatric pulmonology.

[313]  G. Sas Treatment for haemophilia by calendar in Hungary , 1997, BMJ.

[314]  O. Dalesio,et al.  Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review , 2007, The Lancet.

[315]  J Chilcott,et al.  A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative. , 2003, Health technology assessment.

[316]  Lain Chalmers Assembling Comparison Groups to Assess the Effects of Health care * , 1997, Journal of the Royal Society of Medicine.

[317]  Milton C. Weinstein,et al.  Recommendations for Reporting Cost-effectiveness Analyses , 1996 .

[318]  Laurence H. Baker,et al.  Clinical Trials: Design, Conduct, and Analysis , 1987 .

[319]  R M Pitkin,et al.  Accuracy of data in abstracts of published research articles. , 1999, JAMA.

[320]  Jon Smith Crossover Trials in Clinical Research: By Stephen Senn. John Wiley & Sons Ltd., 1993. pp. xv + 266. £24.95. ISBN 0-471-93493-3 , 1993 .

[321]  M. Buyse Interim analyses, stopping rules and data monitoring in clinical trials in Europe. , 1993, Statistics in medicine.

[322]  D G Altman,et al.  Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. , 1994, JAMA.

[323]  T. Kiviluoto,et al.  Randomised trial of laparoscopic versus open cholecystectomy for acute and gangrenous cholecystitis , 1998, The Lancet.

[324]  Brian Hutton,et al.  Does analysis using “last observation carried forward” introduce bias in dementia research? , 2008, Canadian Medical Association Journal.

[325]  M. Egger,et al.  Who benefits from medical interventions? , 1994, BMJ.

[326]  Steve McDonald,et al.  Development of the Cochrane Collaboration’s Central Register of Controlled Clinical Trials , 2002, Evaluation & the health professions.

[327]  M. Gardner,et al.  Confidence intervals rather than P values: estimation rather than hypothesis testing. , 1986, British medical journal.

[328]  M. Gardner,et al.  Statistical guidelines for contributors to medical journals. , 1983, British medical journal.

[329]  R. Ferrari,et al.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[330]  Douglas G Altman,et al.  Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study , 2008, BMJ : British Medical Journal.

[331]  S. Carley,et al.  An open prospective randomised trial to reduce the pain of blood glucose testing: ear versus thumb , 2000, BMJ : British Medical Journal.

[332]  G. Leung,et al.  Quality of Reporting of Key Methodological Items of Randomized Controlled Trials in Clinical Ophthalmic Journals , 2007, Ophthalmic epidemiology.

[333]  M. Gold,et al.  Panel on cost-effectiveness in health and medicine. , 1996, Medical care.

[334]  A. Mantingh,et al.  Randomised controlled trial of magnetic-resonance pelvimetry in breech presentation at term , 1997, The Lancet.

[335]  D. G. Altman,et al.  Randomisation and baseline comparisons in clinical trials , 1990, The Lancet.

[336]  R. Buchbinder,et al.  Effectiveness of low-Dye taping for the short-term treatment of plantar heel pain: a randomised trial , 2006, BMC musculoskeletal disorders.

[337]  Dwight Lemon,et al.  Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1 , 1987 .

[338]  C. Gamble,et al.  Identification and impact of outcome selection bias in meta‐analysis , 2005, Statistics in medicine.

[339]  D. Moher,et al.  Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews , 1996, The Lancet.

[340]  Phil Barton,et al.  Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial , 2000, The Lancet.